Glaxosmithkline | Beneficio Bruto En Ventas



Gross Profit On Sales Cambio Fecha
AbbVie USD 9.34B 1.36B 2025-03
Amgen USD 6.17B 624M 2025-06
AstraZeneca USD 11.98B 637M 2025-06
Aurora Cannabis CAD 9.35M 6.18M 2024-12
Bausch Health Companies USD 1.77B 208M 2025-06
Bristol-Myers Squibb USD 8.9B 714M 2025-06
Canopy Growth CAD 24.1M 2.26M 2024-12
Corcept Therapeutics USD 191M 36.19M 2025-06
Drreddys Laboratories INR 49.05B 1.28B 2024-12
Eli Lilly USD 13.11B 2.61B 2025-06
GlaxoSmithKline GBP 5.82B 229M 2025-06
Glaxosmithkline GBP 5.6B 94M 2024-12
J&J USD 14.6B 816M 2025-03
Merck USD 12.99B 224M 2025-06
Novartis USD 11.51B 1.12B 2025-06
Pacira USD 125.91M 8.71M 2025-06
Perrigo USD 362.9M 29.4M 2025-06
Pfizer USD 10.88B 248M 2025-06
Prestige Brands USD 140.33M 29.68M 2025-06
Roche Holding CHF 11.69B 48M 2024-12
Sanofi EUR 7.74B 26M 2025-06
Supernus Pharmaceuticals USD 127.81M 6.25M 2025-06
Takeda JPY 722.01B 50.69B 2025-06
Teva Pharmaceutical Industries USD 2.1B 188M 2025-06
Zoetis USD 1.78B 180M 2025-06


Glaxosmithkline Beneficio Bruto En Ventas - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Aug 2025.